Judge halts Trump's $11 billion public health cuts
A federal judge in Rhode Island has issued a sweeping order preventing the Trump administration from cutting $11 billion in public health grants, a move that preserves critical funding for 23 states and the District of Columbia as legal proceedings continue.
The Department of Health and Human Services (HHS) had announced on March 24 that it would terminate billions in grants that were originally allocated by Congress during the pandemic. These funds have supported a range of initiatives, including COVID-19 response, mental health, substance abuse treatment, and vaccination programs.
The sudden cutoff prompted a coalition of Democratic-led states to file a lawsuit, arguing that the loss of funding would devastate essential public health infrastructure and that states had not been given time to prepare for the financial shock.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze